BMS’s Baraclude overcame generic attacks

BMS’s Baraclude, which had continuously lost its position due to the attack of generics, has come back on stabilization.

According to the industry concerned on the 14^th, BMS’s Baraclude had successfully led an agreement at the Pusan National University Hospital’s drug bidding against Dong-A Pharmaceutical’s Baracle, CJ’s Enteone and Bukwang Pharm’s Entecavir.

Since the hospital uses both in- ...